Characteristics of Jupiter’s X‐ray auroral hot spot emissions using Chandra

To help understand and determine the driver of jovian auroral X-rays, we present the first statistical study to focus on the morphology and dynamics of the jovian northern hot spot (NHS) using Chandra data. The catalogue we explore dates from 18 December 2000 up to and including 8 September 2019. Using a numerical criterion, we characterize the typical and extreme behaviour of the concentrated NHS emissions across the catalogue. The mean power of the NHS is found to be 1.91 GW with a maximum brightness of 2.02 Rayleighs (R), representing by far the brightest parts of the jovian X-ray spectrum. We report a statistically significant region of emissions at the NHS center which is always present, the averaged hot spot nucleus (AHSNuc), with mean power of 0.57 GW and inferred average brightness of ∼ 1.2 R. We use a flux equivalence mapping model to link this distinct region of X-ray output to a likely source location and find that the majority of mappable NHS photons emanate from the pre-dusk to pre-midnight sector, coincident with the dusk flank boundary. A smaller cluster maps to the noon magnetopause boundary, dominated by the AHSNuc, suggesting that there may be multiple drivers of X-ray emissions. On application of timing analysis techniques (Rayleigh, Monte Carlo, Jackknife), we identify several instances of statistically significant quasi-periodic oscillations (QPOs) in the NHS photons ranging from ∼ 2.3-min to 36.4-min, suggesting possible links with ultra-low frequency activity on the magnetopause boundary (e.g. dayside reconnection, Kelvin-Helmholtz instabilities)

Identifying the Variety of Jovian X-Ray Auroral Structures: Tying the Morphology of X-Ray Emissions to Associated Magnetospheric Dynamics

We define the spatial clustering of X-rays within Jupiter's northern auroral regions by classifying their distributions into “X-ray auroral structures.” Using data from Chandra during Juno's main mission observations (24 May 2016 to 8 September 2019), we define five X-ray structures based on their ionospheric location and calculate the distribution of auroral photons. The morphology and ionospheric location of these structures allow us to explore the possibility of numerous X-ray auroral magnetospheric drivers. We compare these distributions to Hubble Space Telescope (HST) and Juno (Waves and MAG) data, and a 1D solar wind propagation model to infer the state of Jupiter's magnetosphere. Our results suggest that the five sub-classes of “X-ray structures” fall under two broad morphologies: fully polar and low latitude emissions. Visibility modeling of each structure suggests the non-uniformity of the photon distributions across the Chandra intervals are likely associated with the switching on/off of magnetospheric drivers as opposed to geometrical effects. The combination of ultraviolet (UV) and X-ray morphological structures is a powerful tool to elucidate the behavior of both electrons and ions and their link to solar wind/magnetospheric conditions in the absence of an upstream solar monitor. Although much work is still needed to progress the use of X-ray morphology as a diagnostic tool, we set the foundations for future studies to continue this vital research

Jupiter's X‐Ray and UV Dark Polar Region

We present 14 simultaneous Chandra X-ray Observatory (CXO)-Hubble Space Telescope (HST) observations of Jupiter's Northern X-ray and ultraviolet (UV) aurorae from 2016 to 2019. Despite the variety of dynamic UV and X-ray auroral structures, one region is conspicuous by its persistent absence of emission: the dark polar region (DPR). Previous HST observations have shown that very little UV emission is produced by the DPR. We find that the DPR also produces very few X-ray photons. For all 14 observations, the low level of X-ray emission from the DPR is consistent (within 2-standard deviations) with scattered solar emission and/or photons spread by Chandra's Point Spread Function from known X-ray-bright regions. We therefore conclude that for these 14 observations the DPR produced no statistically significant detectable X-ray signature

The Therapeutic effect of Memantine through the Stimulation of Synapse Formation and Dendritic Spine Maturation in Autism and Fragile X Syndrome

Although the pathogenic mechanisms that underlie autism are not well understood, there is evidence showing that metabotropic and ionotropic glutamate receptors are hyper-stimulated and the GABAergic system is hypo-stimulated in autism. Memantine is an uncompetitive antagonist of NMDA receptors and is widely prescribed for treatment of Alzheimer's disease treatment. Recently, it has been shown to improve language function, social behavior, and self-stimulatory behaviors of some autistic subjects. However the mechanism by which memantine exerts its effect remains to be elucidated. In this study, we used cultured cerebellar granule cells (CGCs) from Fmr1 knockout (KO) mice, a mouse model for fragile X syndrome (FXS) and syndromic autism, to examine the effects of memantine on dendritic spine development and synapse formation. Our results show that the maturation of dendritic spines is delayed in Fmr1-KO CGCs. We also detected reduced excitatory synapse formation in Fmr1-KO CGCs. Memantine treatment of Fmr1-KO CGCs promoted cell adhesion properties. Memantine also stimulated the development of mushroom-shaped mature dendritic spines and restored dendritic spine to normal levels in Fmr1-KO CGCs. Furthermore, we demonstrated that memantine treatment promoted synapse formation and restored the excitatory synapses to a normal range in Fmr1-KO CGCs. These findings suggest that memantine may exert its therapeutic capacity through a stimulatory effect on dendritic spine maturation and excitatory synapse formation, as well as promoting adhesion of CGCs

Comparing Jupiter's equatorial X-ray emissions with solar X-ray flux over 19 years of the Chandra mission

We present a statistical study of Jupiter’s disk X-ray emissions using 19 years of Chandra X-Ray Observatory (CXO) observations. Previous work has suggested that these emissions are consistent with solar X-rays elastically scattered from Jupiter’s upper atmosphere. We showcase a new Pulse Invariant (PI) filtering method that minimises instrumental effects which may produce unphysical trends in photon counts across the nearly-two-decade span of the observations. We compare the CXO results with solar X-ray flux data from the Geostationary Operational Environmental Satellites (GOES) X-ray Sensor (XRS) for the wavelength band 1-8 Å (long channel), to quantify the correlation between solar activity and jovian disk counts. We find a statistically significant Pearson’s Correlation Coefficient (PCC) of 0.9, which confirms that emitted jovian disk X-rays are predominantly governed by solar activity. We also utilise the high spatial resolution of the High Resolution Camera Instrument (HRC-I) on board the CXO to map the disk photons to their positions on Jupiter’s surface. Voronoi tessellation diagrams were constructed with the JRM09 (Juno Reference Model through Perijove 9) internal field model overlaid to identify any spatial preference of equatorial photons. After accounting for area and scattering across the curved surface of the planet, we find a preference of jovian disk emission at 2-3.5 Gauss surface magnetic field strength. This suggests that a portion of the disk X-rays may be linked to processes other than solar scattering: the spatial preference associated with magnetic field strength may imply increased precipitation from the radiation belts, as previously postulated

Intra-articular enzyme replacement therapy with rhIDUA is safe, well-tolerated, and reduces articular GAG storage in the canine model of mucopolysaccharidosis type I

Background: Treatment with intravenous enzyme replacement therapy and hematopoietic stem cell transplantation for mucopolysaccharidosis (MPS) type I does not address joint disease, resulting in persistent orthopedic complications and impaired quality of life. A proof-of-concept study was conducted to determine the safety, tolerability, and efficacy of intra-articular recombinant human iduronidase (IA-rhIDUA) enzyme replacement therapy in the canine MPS I model. Methods: Four MPS I dogs underwent monthly rhIDUA injections (0.58. mg/joint) into the right elbow and knee for 6. months. Contralateral elbows and knees concurrently received normal saline. No intravenous rhIDUA therapy was administered. Monthly blood counts, chemistries, anti-rhIDUA antibody titers, and synovial fluid cell counts were measured. Lysosomal storage of synoviocytes and chondrocytes, synovial macrophages and plasma cells were scored at baseline and 1. month following the final injection. Results: All injections were well-tolerated without adverse reactions. One animal required prednisone for spinal cord compression. There were no clinically significant abnormalities in blood counts or chemistries. Circulating anti-rhIDUA antibody titers gradually increased in all dogs except the prednisone-treated dog; plasma cells, which were absent in all baseline synovial specimens, were predominantly found in synovium of rhIDUA-treated joints at study-end. Lysosomal storage in synoviocytes and chondrocytes following 6. months of IA-rhIDUA demonstrated significant reduction compared to tissues at baseline, and saline-treated tissues at study-end. Mean joint synovial GAG levels in IA-rhIDUA joints were 8.62 ± 5.86 μg/mg dry weight and 21.6 ± 10.4 μg/mg dry weight in control joints (60% reduction). Cartilage heparan sulfate was also reduced in the IA-rhIDUA joints (113 ± 39.5. ng/g wet weight) compared to saline-treated joints (142 ± 56.4. ng/g wet weight). Synovial macrophage infiltration, which was present in all joints at baseline, was abolished in rhIDUA-treated joints only. Conclusions: Intra-articular rhIDUA is well-tolerated and safe in the canine MPS I animal model. Qualitative and quantitative assessments indicate that IA-rhIDUA successfully reduces tissue and cellular GAG storage in synovium and articular cartilage, including cartilage deep to the articular surface, and eliminates inflammatory macrophages from synovial tissue. Clinical relevance: The MPS I canine IA-rhIDUA results suggest that clinical studies should be performed to determine if IA-rhIDUA is a viable approach to ameliorating refractory orthopedic disease in human MPS I. © 2014 Elsevier Inc